Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

PMVP vs RAIN

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
PMVP
PMV Pharmaceuticals, Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$77M
5Y Perf.+2.1%
RAIN
Rain Enhancement Technologies Holdco Inc

Renewable Utilities

UtilitiesNASDAQ • US
Market Cap$4M
5Y Perf.-49.7%

PMVP vs RAIN — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
PMVP logoPMVP
RAIN logoRAIN
IndustryBiotechnologyRenewable Utilities
Market Cap$77M$4M
Revenue (TTM)$0.00$0.00
Net Income (TTM)$-83M$-6M
Total Debt$1M$4M
Cash & Equiv.$41M$33K

PMVP vs RAINLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

PMVP
RAIN
StockJan 25May 26Return
PMV Pharmaceuticals… (PMVP)100102.1+2.1%
Rain Enhancement Te… (RAIN)10050.3-49.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: PMVP vs RAIN

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: PMVP leads in 5 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
PMVP
PMV Pharmaceuticals, Inc.
The Income Pick

PMVP carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • beta 0.76
  • EPS growth 21.0%
  • Lower volatility, beta 0.76, Low D/E 0.7%, current ratio 12.22x
Best for: income & stability and growth exposure
RAIN
Rain Enhancement Technologies Holdco Inc
The Long-Run Compounder

RAIN is the clearest fit if your priority is long-term compounding.

  • -74.2% 10Y total return vs PMVP's -96.1%
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthPMVP logoPMVP-65.1% revenue growth vs RAIN's -121.2%
Quality / MarginsPMVP logoPMVP5.6% margin vs RAIN's -2.4%
Stability / SafetyPMVP logoPMVPBeta 0.76 vs RAIN's 1.20
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)PMVP logoPMVP+66.7% vs RAIN's -62.5%
Efficiency (ROA)PMVP logoPMVP-51.0% ROA vs RAIN's -298.9%

PMVP vs RAIN — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLPMVPLAGGINGRAIN

Income & Cash Flow (Last 12 Months)

Insufficient data to determine a leader in this category.

PMVP and RAIN operate at a comparable scale, with $0 and $0 in trailing revenue.

MetricPMVP logoPMVPPMV Pharmaceutica…RAIN logoRAINRain Enhancement …
RevenueTrailing 12 months$0$0
EBITDAEarnings before interest/tax-$92M-$5M
Net IncomeAfter-tax profit-$83M-$6M
Free Cash FlowCash after capex-$73M-$4M
Gross MarginGross profit ÷ Revenue
Operating MarginEBIT ÷ Revenue
Net MarginNet income ÷ Revenue
FCF MarginFCF ÷ Revenue
Rev. Growth (YoY)Latest quarter vs prior year
EPS Growth (YoY)Latest quarter vs prior year-8.1%
Insufficient data to determine a leader in this category.

Valuation Metrics

PMVP leads this category, winning 1 of 1 comparable metric.
MetricPMVP logoPMVPPMV Pharmaceutica…RAIN logoRAINRain Enhancement …
Market CapShares × price$77M$4M
Enterprise ValueMkt cap + debt − cash$37M$7M
Trailing P/EPrice ÷ TTM EPS-1.27x-0.82x
Forward P/EPrice ÷ next-FY EPS est.
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple
Price / SalesMarket cap ÷ Revenue
Price / BookPrice ÷ Book value/share0.42x
Price / FCFMarket cap ÷ FCF
PMVP leads this category, winning 1 of 1 comparable metric.

Profitability & Efficiency

PMVP leads this category, winning 3 of 4 comparable metrics.

On the Piotroski fundamental quality scale (0–9), RAIN scores 3/9 vs PMVP's 2/9, reflecting mixed financial health.

MetricPMVP logoPMVPPMV Pharmaceutica…RAIN logoRAINRain Enhancement …
ROE (TTM)Return on equity-55.3%
ROA (TTM)Return on assets-51.0%-3.0%
ROICReturn on invested capital-38.0%
ROCEReturn on capital employed-41.2%
Piotroski ScoreFundamental quality 0–923
Debt / EquityFinancial leverage0.01x
Net DebtTotal debt minus cash-$40M$3M
Cash & Equiv.Liquid assets$41M$32,604
Total DebtShort + long-term debt$1M$4M
Interest CoverageEBIT ÷ Interest expense-148.90x
PMVP leads this category, winning 3 of 4 comparable metrics.

Total Returns (Dividends Reinvested)

PMVP leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in RAIN five years ago would be worth $2,575 today (with dividends reinvested), compared to $413 for PMVP. Over the past 12 months, PMVP leads with a +66.7% total return vs RAIN's -62.5%. The 3-year compound annual growth rate (CAGR) favors PMVP at -33.8% vs RAIN's -36.4% — a key indicator of consistent wealth creation.

MetricPMVP logoPMVPPMV Pharmaceutica…RAIN logoRAINRain Enhancement …
YTD ReturnYear-to-date+17.9%-62.4%
1-Year ReturnPast 12 months+66.7%-62.5%
3-Year ReturnCumulative with dividends-70.9%-74.2%
5-Year ReturnCumulative with dividends-95.9%-74.2%
10-Year ReturnCumulative with dividends-96.1%-74.2%
CAGR (3Y)Annualised 3-year return-33.8%-36.4%
PMVP leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

PMVP leads this category, winning 2 of 2 comparable metrics.

PMVP is the less volatile stock with a 0.76 beta — it tends to amplify market swings less than RAIN's 1.20 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PMVP currently trades 77.1% from its 52-week high vs RAIN's 19.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricPMVP logoPMVPPMV Pharmaceutica…RAIN logoRAINRain Enhancement …
Beta (5Y)Sensitivity to S&P 5000.76x1.20x
52-Week HighHighest price in past year$1.88$9.58
52-Week LowLowest price in past year$0.81$1.80
% of 52W HighCurrent price vs 52-week peak+77.1%+19.6%
RSI (14)Momentum oscillator 0–10049.236.6
Avg Volume (50D)Average daily shares traded727K18K
PMVP leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.
MetricPMVP logoPMVPPMV Pharmaceutica…RAIN logoRAINRain Enhancement …
Analyst RatingConsensus buy/hold/sell
Price TargetConsensus 12-month target
# AnalystsCovering analysts
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

PMVP leads in 4 of 6 categories — strongest in Valuation Metrics and Profitability & Efficiency.

Best OverallPMV Pharmaceuticals, Inc. (PMVP)Leads 4 of 6 categories
Loading custom metrics...

PMVP vs RAIN: Frequently Asked Questions

7 questions · data-driven answers · updated daily

01

Which is the better long-term investment — PMVP or RAIN?

Over the past 5 years, Rain Enhancement Technologies Holdco Inc (RAIN) delivered a total return of -74.

2%, compared to -95. 9% for PMV Pharmaceuticals, Inc. (PMVP). Over 10 years, the gap is even starker: RAIN returned -74. 2% versus PMVP's -96. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

02

Which is safer — PMVP or RAIN?

By beta (market sensitivity over 5 years), PMV Pharmaceuticals, Inc.

(PMVP) is the lower-risk stock at 0. 76β versus Rain Enhancement Technologies Holdco Inc's 1. 20β — meaning RAIN is approximately 58% more volatile than PMVP relative to the S&P 500.

03

Which is growing faster — PMVP or RAIN?

On earnings-per-share growth, the picture is similar: PMV Pharmaceuticals, Inc.

grew EPS 21. 0% year-over-year, compared to -34. 9% for Rain Enhancement Technologies Holdco Inc. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

04

Which has better profit margins — PMVP or RAIN?

PMV Pharmaceuticals, Inc.

(PMVP) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Rain Enhancement Technologies Holdco Inc — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PMVP leads at 0. 0% versus 0. 0% for RAIN. At the gross margin level — before operating expenses — PMVP leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

05

Which pays a better dividend — PMVP or RAIN?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

06

Is PMVP or RAIN better for a retirement portfolio?

For long-horizon retirement investors, PMV Pharmaceuticals, Inc.

(PMVP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 76)). Both have compounded well over 10 years (PMVP: -96. 1%, RAIN: -74. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

07

What are the main differences between PMVP and RAIN?

These companies operate in different sectors (PMVP (Healthcare) and RAIN (Utilities)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

PMVP

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

RAIN

Quality Business

  • Sector: Utilities
  • Market Cap > $100B
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.